Morningstar

Alvotech ALVO

Stock XICE Rating as of Oct 26, 2026

News

Alvotech Shares Rise After FDA Okays Simlandi Manufacturing Process

Global News Select Oct 20, 2026, 2:00:00 PM
Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

GlobeNewswire Oct 20, 2026, 8:30:00 AM
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

GlobeNewswire Oct 14, 2026, 8:30:00 AM
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

GlobeNewswire Oct 6, 2026, 8:36:45 PM
Alvotech Shares Rise After FDA Approves Additional Manufacturing for Simlandi

Global News Select Oct 5, 2026, 4:49:00 PM
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

GlobeNewswire Oct 5, 2026, 8:00:00 AM
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

GlobeNewswire Aug 31, 2026, 8:30:00 AM
Alvotech to present at upcoming investor conferences in September

GlobeNewswire Aug 27, 2026, 12:00:00 PM
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

GlobeNewswire Aug 21, 2026, 1:00:00 PM
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

GlobeNewswire Aug 19, 2026, 8:30:00 PM
Alvotech to Report Financial Results for H1 2026

GlobeNewswire Aug 10, 2026, 12:00:00 PM
Alvotech Shares Rise After Wrapping FDA Facility Inspection

Global News Select Jul 29, 2026, 4:39:00 PM
Alvotech announces successful closure of FDA inspection of manufacturing facility

GlobeNewswire Jul 29, 2026, 1:25:33 PM
Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar

Global News Select Nov 3, 2025, 3:14:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.